Research led by the University of Chicago Medicine showcases a new therapy to re-engage the heart’s natural electrical pathways rather than bypassing them. The implications point toward more treatment options for heart failure patients who additionally are afflicted...
CV
Category
FDA Seek to Approve Febuxostat for Gout Despite Potential CV Risks
Medscape reports that the FDA’s Arthritis Advisory Committee (AAC) and Drug Safety and Risk Management (DSaRM) Advisory Committee voted by a large margin (19 yes, 2 no 1 abstention) to still recommend febuxostat (Uloric, Takeda) for some patients with gout-related...
Trial Watch: Novo Nordisk’s Liraglutide Significantly Reduces Major Cardiac Events in Elderly
Liraglutide is marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing a separate strength in the U.S. and E.U. under the brand name Saxenda as a treatment...